Pasithea Therapeutics (US:KTTA) — Company Overview, News & Financial Data
Pasithea Therapeutics develops innovative treatments for psychiatric and neurological disorders, aiming to transform mental health care.
About Pasithea Therapeutics
Pasithea Therapeutics (NASDAQ:KTTA) focuses on developing innovative treatments for psychiatric and neurological disorders. The company is deeply engaged in pursuing cutting-edge research and projects aimed at understanding and potentially curing debilitating conditions such as depression, anxiety, and multiple sclerosis. By leveraging advanced science and technology, Pasithea Therapeutics is on a mission to improve mental health care and offer new hope to patients through novel therapeutic approaches. Their objectives are centered around bringing breakthrough therapies from the lab to the clinic, ultimately aiming to transform the way these diseases are treated worldwide.
Snapshot
Operations
Products and/or services of Pasithea Therapeutics
- Development of novel therapies for psychiatric and neurological disorders, focusing on innovative treatments for depression and anxiety.
- Exploration of ketamine therapy as a rapid-acting treatment for mood and anxiety disorders.
- Research into psychedelic-based treatments aiming to address mental health diseases with significant unmet needs.
- Advancement of monoclonal antibody therapies for the treatment of neurodegenerative diseases, including ALS and Alzheimer’s.
- Collaboration with academic and medical institutions to facilitate clinical trials and research into cutting-edge psychiatric treatments.
- Investment in the development of proprietary technology platforms to enhance drug discovery and development processes.
Pasithea Therapeutics executive team
- Dr. Lawrence Steinman BA, M.D., Ph.D.Co-Founder, MD & Executive Chairman
- Dr. Tiago Reis Marques M.D., Ph.D.CEO & Director
- Mr. Daniel H. SchneidermanChief Financial Officer